melagatran has been researched along with lansoprazole in 3 studies
| Studies (melagatran) | Trials (melagatran) | Recent Studies (post-2010) (melagatran) | Studies (lansoprazole) | Trials (lansoprazole) | Recent Studies (post-2010) (lansoprazole) |
|---|---|---|---|---|---|
| 185 | 32 | 19 | 2,281 | 803 | 600 |
| Protein | Taxonomy | melagatran (IC50) | lansoprazole (IC50) |
|---|---|---|---|
| phosphoethanolamine/phosphocholine phosphatase isoform 1 | Homo sapiens (human) | 0.434 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.995 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 5.3148 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.3367 | |
| WD repeat-containing protein 5 | Homo sapiens (human) | 5.9 | |
| Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | 5.9 | |
| Indoleamine 2,3-dioxygenase 2 | Mus musculus (house mouse) | 8.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
3 other study(ies) available for melagatran and lansoprazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |